

Special Issue

Discoveries in Targeted Therapies for Melanoma: From Molecular Mechanisms to Therapeutics

Message from the Guest Editor

The majority of skin cancer-related deaths is caused by malignant melanoma, a tumor originating from neural crest-derived melanocytes, and novel molecular strategies for the improved detection and treatment of melanoma are of substantial clinical significance. This Special Issue of *Cancers*, entitled 'Discoveries in Targeted Therapy for Melanoma: From Molecular Mechanisms to Therapeutics', aims at gathering original research and review papers on the current understanding of novel molecular mechanisms and therapeutic opportunities that might benefit melanoma patients in the near future. Thank you for your research efforts. Please consider contributing to this Special Issue.

Guest Editor

Dr. Georg Thomas Wondrak

R. Ken Coit College of Pharmacy and UA Cancer Center, The University of Arizona, Tucson, AZ, USA

Deadline for manuscript submissions

closed (1 November 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/191568

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)